Clinical trial NCT06888063: Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery
Official title: Preventing Liver Recurrence After Partial Hepatectomy for Intrahepatic Cholangiocarcinoma Using Adjuvant Hepatic Arterial Infusion Pump Chemotherapy - PUMP IV Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Intrahepatic Bile Duct Cancer
Intrahepatic Cholangiocarcinoma (Icc)
Intrahepatic Bile Duct Carcinoma
Intrahepatic Cholangiocarcinoma
Keywords: PUMP
PUMP IV
Hepatic Arterial Infusion Chemotherapy
Hepatic Arterial Infusion Pump chemotherapy
HAIP
HAIC
Intrahepatic cholangiocarcinoma
iCCA
Floxuridin
Chemopump
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
Collaborators: name: Koningin Wilhelmina Fonds
First posted: 2025-03-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery. The main questions it aims to answer are:

* Does addition of chemotherapy by means of a chemo pump lead to less return of disease within the liver two years after surgery?
* Does addition of chemotherapy by means of a chemo pump lead to longer survival of patients?
* Does addition of chemotherapy by means of a chemo pump lead to an increase in quality of life?

Participants will receive an implanted chemo pump, through which additional chemotherapy will be given to the liver in addition to surgery.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* ECOG or WHO performance status 0 or 1
* Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care.
* Patient is able to undergo a laparotomy.
* Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement.
* Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old)
* Absolute neutrophil count (ANC) ≥ 1.5 x 10\^ 9/L
* White blood cell count (WBC) ≥ 2.5 x 10\^9/L
* Platelets ≥ 100 x 10\^9/L
* Glomerular filtration rate (GFR) ≥ 30 ml/min
* Haemoglobin (Hb) ≥ 5.5 mmol/L
* Total bilirubin ≤ 25 µmol/L
* Written informed consent must be given according to ICH/good clinical practice (GCP), and national/local regulations.

Exclusion Criteria:

* Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible.
* Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years.
* Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency
* Prior hepatic radiation, ablation, or resection for iCCA.
* Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed.
* (Partial) portal vein thrombosis in future liver remnant.
* Pregnant or lactating women.
* History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy.
* Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
* Organ allografts requiring immunosuppressive therapy.
* Serious infections (uncontrolled or requiring treatment).
* Participation in another interventional study for iCCA with survival as outcome.
* Participation in another prospective study with an interventional medical product.
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Primary outcomes:
measure: Two-year hepatic recurrence free survival (hRFS)
timeFrame: From pump implantation until 2 years after that surgery
Secondary outcomes:
measure: Overall recurrence free survival (RFS)
timeFrame: From pump implantation until the earliest return of disease in the body during the study (up to 5 years after inclusion)
measure: Overall survival (OS)
timeFrame: From pump implantation until death or lost to follow-up during the study (up to 5 years after inclusion)
measure: Post-operative complications
timeFrame: From pump implantation until 90 days after surgery
measure: Chemotherapy related adverse events (AEs)
timeFrame: From inclusion until 4 weeks after the end of treatment with chemotherapy
measure: Proportion of patients started with HAIP chemotherapy
timeFrame: From pump implantation until the first cycle of HAIP chemotherapy, on average between 4 and 16 weeks after implantation of the HAIP chemopump
measure: Quality of life: EORTC QLQ-30
timeFrame: From inclusion until 5 years after surgery
measure: Quality of life: EQ-5D
timeFrame: From inclusion until 5 years after surgery
measure: Cost-effectiveness
timeFrame: From implantation of the chemo pump until 2 years after (=timeframe of the primary outcome)
measure: Predictive biomarkers in the blood for efficacy of HAIP chemotherapy
timeFrame: From implantation of the chemo pump until 1 year after surgery or return of disease (whichever comes first)
measure: Predictive biomarkers from liver tissue for efficacy of HAIP chemotherapy
timeFrame: From resection until 25 years after (conform applicable laws)
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus Medical Center
state: South-Holland
Study officials:
affiliation: Erasmus Medical Center
name: Bas Groot Koerkamp, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: